BioLine RX Ltd
Change company Symbol lookup
Select an option...
BLRX BioLine RX Ltd
ACC American Campus Communities Inc
PNFP Pinnacle Financial Partners Inc
SYF Synchrony Financial
TRV Travelers Companies Inc
IBM International Business Machines Corp
T AT&T Inc
MRK Merck & Co Inc
PFE Pfizer Inc
C Citigroup Inc
Go

Health Care : Biotechnology | Small Cap Value
Based in Israel
Company profile

BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Closing Price
$2.63
Day's Change
-0.05 (-1.87%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.65
Day's Low
2.53
Volume
(Average)
Volume:
390,411

10-day average volume:
434,567
390,411

There is no peer information for BLRX.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2021. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.